Navigation Links
Novavax Announces Early Retirement of $17 Million of Convertible Debt
Date:4/29/2009

nt vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
2. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
3. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
5. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
6. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
7. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
8. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
9. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
10. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
11. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... circuits are based on electrons, but one of the ... circuits, i.e. circuits based on light (photons) instead of ... create a stream of single photons and control their ... of attempts to achieve this control, but now scientists ... a steady stream of photons emitted one at a ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., the first ... hand sanitizer, asks food processors and food handling professionals ... sanitizer they’re currently using to Best Sanitizers’ Alpet® ... critical to fighting cross-contamination and the spread of pathogens ... there are key criteria that make a hand sanitizer ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... and the University of California, Los Angeles (UCLA) have concluded ... chemistry for the rapid and robust labeling of proteins, peptides ... Emission Tomography (PET). "We are pleased ... cutting-edge work being developed by the Crump Institute," said Dr. ...
... Geim, a recipient of the 2010 Nobel Prize for graphene, ... electrons can magnetise graphene. The results, reported in ... the field of spintronics. Spintronics is a group of ... in addition to its fundamental electric charge that is exploited ...
... April 15, 2011 Carmell Therapeutics, a company that ... of injured tissues, has closed on a Series A ... facility and collect data for early clinical validation for ... was led by Harbor Light Capital Partners, a private ...
Cached Biology Technology:ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology 2New spin on graphene 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3
(Date:8/31/2014)... A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria ... stomach cramps, has been developed by a team at ... the research team has demonstrated that it is possible ... which would lead to rapid diagnosis of the ... could be possible to identify different strains of the ...
(Date:8/31/2014)... past several decades, malaria diagnosis has changed very little. After ... the blood across a glass slide, stains it with a ... parasite, which causes the disease. This approach gives an accurate ... an important measure of disease severity but is not ... research team from the Singapore-MIT Alliance for Research and Technology ...
(Date:8/29/2014)... from the University of Texas Medical Branch at Galveston has ... antibodies can completely protect monkeys against a lethal dose of ... time when the disease is severe. , Thomas Geisbert, professor ... Nature discussing advances in Ebola treatment research. The filoviruses ... most deadly of pathogens, with fatality rates of up to ...
Breaking Biology News(10 mins):Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2
... , April 30, 2013 /PRNewswire-iReach/ -- Clinilabs, an early phase ... industry, today announced the arrival of Dr. Admir ... provide expertise in the development of drugs to treat pain, ... clinical trials. Dr. Admir Hadzic ...
... integrates three large sets of genomic data available through ... that might predict survival in patients with the most ... researchers at the Ohio State University Comprehensive Cancer Center ... Solove Research Institute (OSUCCC James) initially analyzed messenger ...
... whales sing complex songs in tropical waters during the ... latitudes at other times of the year. NOAA ... whale movements to acoustic behavior on a feeding ground ... published April 10 in the journal PLOS ONE ...
Cached Biology News:Clinilabs Welcomes Anesthesiologist Dr. Admir Hadzic Who Will Provide CSF/cCSF Capabilities For Clinilabs 2Big data analysis identifies prognostic RNA markers in a common form of breast cancer 2Researchers track singing humpback whales on a Northwest Atlantic feeding ground 2
... is used to perform runs with ... the Experion automated electrophoresis system. The ... simulated gel views and summarizes size, ... Results table. This software is for ...
... Top cover cold rolled steel with stove ... surface polyethylene Front, ... 3 UV lamps Internal ... interlocked with fluorescent light Lighting ...
...
... this set of Antibody Microarray slides ... a total of over 2100 spots,including ... control. Antibodies belonging to many important ... cycle progression, signal transduction and gene ...
Biology Products: